ClinicalTrials.gg
Status unknownNCT01845844ROTATEUpdated Sep 17, 2014

Ranibizumab For Persistent Diabetic Macular Edema After Bevacizumab

A Phase 1/2 interventional study of Ranibizumab 0.3mg/0.05cc in Diabetic Macular Edema, sponsored by Southeast Retina Center, Georgia. Status unknown at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-09-17.

Sponsored by Southeast Retina Center, Georgia · Phase 1/2, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Sep 2014), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 91 studies testing ranibizumab in Macular Edema — none open to participants now, none under way, none of them phase 3. Ranibizumab · Macular Edema.

Planned enrollment
61st of 91
30 · median 50
Started
2013
with 9 others
Phase 1/2
6 of 91
none open now
Registered
48th of 91
by date

Among the 91 studies testing ranibizumab in Macular Edema, this one is the 61st largest by planned enrollment, is one of 10 that started in 2013, is one of 6 in phase 1/2, and was the 48th registered.

Macular Edema

759 studies on the registry are indexed under Macular Edema; 66 are open to participants now.

Browse Macular Edema studies →

Open to participants now

None of the 91 studies testing ranibizumab in Macular Edema is open now. The open studies under Macular Edema, anywhere →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 91 studies testing ranibizumab in Macular Edema as a file.
02

Study summary

This is an open-label, Phase I/II study of Intravitreally administered 0.3mg ranibizumab in subjects with persistent Diabetic Macular Edema (DME) after recent and frequent bevacizumab (at least 2 bevacizumab intravitreal injections within 2 months prior to enrollment and at least 6 bevacizumab injections within 9 months of enrollment).

Read the detailed description

30 eyes will be randomized in a 1:2 ratio (Group A= 10 patients; Group B= 20 patients) Group A: ("monthly group")- Consented patient with enrolled eye will receive 12 monthly required injections of 0.3mg ranibizumab over 1 year OR Group B: ("As needed (PRN) Group")- Consented patient with enrolled eye will receive 6 monthly required injections of 0.3mg ranibizumab for 6 months, followed by as needed (PRN) dosing (required ranibizumab if DME persistent on Optical Coherence Tomography (OCT) and Early Treatment Diabetic Retina Study (ETDRS) Best Corrected Visual Acuity (BCVA) \<20/20) for 6 months.

03

Conditions studied

  • Diabetic Macular Edema

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to provide written and comply with study assessments for the full duration of the study.
  • >=18 years
  • Type I/II diabetes mellitus
  • Central-involved DME in study eye (OCT CSF >=275um on Heidelberg Spectralis spectral domain OCT with evidence of intraretinal or subretinal fluid or cysts)
  • Definite retinal thickening due to diabetic macular edema involving the center of the macula.
  • Media clarity, pupillary dilation and individual cooperation for adequate fungus photography and fluorescein angiography.
  • Visual Acuity score in study eye \<=80 and >=20 (approximate Snellen equivalent 20/25 to 20/400).
  • History of at least 6 intravitreal bevacizumab injections within the past 9 months and 2 intravitreal bevacizumab injections within the past 2 months.
  • No history of an anti-VEGF treatment for DME in the past 3 weeks.
  • No other DME treatment for DME, other than bevacizumab, in the study eye at any time in the past 3 months.
  • No history of major ocular surgery in the study eye within prior 3 months or anticipated within the next six months following randomization.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or lactation
  • Any other condition that the investigator believes would pose a significant hazard to the subject if the therapy were initiated
  • Participation in another medical investigation or trial within 30 days of randomization
  • Known allergy to ranibizumab
  • Acute cardiovascular event requiring hospitalization within the past 3 months
  • Systemic anti-VEGF or pro-VEGF treatment within 3 months prior to randomization or anticipated use during the study
  • Macular edema is considered to be due to a cause other than DME
  • An ocular condition is present such that, in the opinion of the investigator, visual acuity loss would not improve from the resolution of macular edema
  • History of intravitreal anti-vascular endothelial growth factor (anti-VEGF) agent other than bevacizumab within 9 months prior to randomization
  • History of panretinal photocoagulation within 3 months prior to randomization or anticipated need for panretinal photocoagulation in the 6 months following randomization
  • Yag capsulotomy performed within 1 month prior to randomization
  • External ocular infection including conjunctivitis, significant blepharitis, etc.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Ranibizumab 0.3mg (12 months)

    Intravitreal injection of ranibizumab 0.3mg/0.05cc

    Drug: Ranibizumab 0.3mg/0.05cc

  • Active comparator
    Ranibizumab 0.3mg (6 months)

    Intravitreal injection of ranibizumab 0.3mg/0.05cc

    Drug: Ranibizumab 0.3mg/0.05cc

Interventions

  • DrugRanibizumab 0.3mg/0.05cc

    Drug page: RanibizumabStudies of RanibizumabRanibizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Group A (Arm A) will receive monthly 0.3mg/0.05cc intravitreal injections for 12 consecutive months. Group B (Arm B) will receive monthly 0.3mg/0.05cc intravitreal injections for the first six months and then PRN for the remaining 6 months per protocol specified criteria.

    Also known as: Lucentis

06

What researchers measure

Primary outcomes

  1. Incidence of ocular and systemic adverse events will be compared between experimental and active comparator groups

    Examples include worsened acuity of greater than 30 letters, retinal detachment, endophthalmitis, cataract progression, vitreous hemorrhage, new PDR or neovascularization of the iris or angle, incidence and severity of other adverse events, as identified by physical examination, subject reporting, and changes in vital signs and will include thromboembolic events, deaths and systemic serious adverse events

    Time frame: 1 year

  2. Severity of ocular and systemic adverse events will be compared between experimental and active comparator groups

    Examples include worsened acuity of greater than 30 letters, retinal detachment, endophthalmitis, cataract progression, vitreous hemorrhage, new PDR or neovascularization of the iris or angle, incidence and severity of other adverse events, as identified by physical examination, subject reporting, and changes in vital signs and will include thromboembolic events, deaths and systemic serious adverse events

    Time frame: 1 year

Secondary outcomes

  1. Efficacy of monthly and monthly followed by PRN dosing of 0.3 mg ranibizumab after persistent DME despite previous bevacizumab therapy

    Examples include proportion of eyes with absence of fluorescein angiographic macular leakage at 12 months; proportion of eyes with unchanged, worsened, or improved fluorescein angiographic macular leakage from baseline at 1, 6 and 12 months; proportion of eyes with unchanged, worsened, or improved fundus photographic DME appearance from baseline at 1, 6 and 12 months; proportion of eyes with new vitreous hemorrhage or traction retinal detachment secondary to Proliferative Diabetic Retinopathy (PDR); proportion of eyes with progression from baseline Non-proliferative Diabetic Retinopathy (NPDR) to PDR

    Time frame: 1 year

Other outcomes

  1. Mean BCVA letter score

    ◦Mean BCVA letter changes from baseline at 1, 3, 6, 9 and 12 months

    Time frame: Baseline, 1, 3, 6, 9, and 12 months

  2. Mean OCT CSF thickness and macular volume

    OCT Central Subfield (CSF) thickness and macular volume mean changes from baseline at 1, 3, 6, 9 and 12 months

    Time frame: Baseline, 1, 3, 6, 9, and 12 months

07

Study locations

1 of 1 sites recruiting
  • Southeast Retina Center, PC
    Augusta, Georgia 30909, United States
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2013, a primary completion of Jan 2015 and a completion of Jan 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2013
First posted
May 3, 2013
Start
Apr 2013
Primary completionEst.
Jan 2015
CompletionEst.
Jan 2015
Last update
Sep 17, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01845844
Lead sponsor
Southeast Retina Center, Georgia
Collaborators
Genentech, Inc.
Responsible party
Dennis M. Marcus, M.D. (Dr. Dennis M. Marcus Principal Investigator, Southeast Retina Center, Georgia) — Principal investigator
First posted
May 3, 2013
Start date
Apr 2013
Primary completion
Jan 2015 (estimated)
Completion
Jan 2015 (estimated)
Last update
Sep 17, 2014

Study contacts

Dennis M Marcus, M.D.
Contact
dmarcus@southeastretina.com
706-650-0061
Dennis M Marcus, M.D.
study director · Southeast Retina Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion